logo
Waist Measure Improved Mortality Prediction in Older Women

Waist Measure Improved Mortality Prediction in Older Women

Medscape08-07-2025
By using waist circumference along with BMI, modest gains were made in predicting which postmenopausal women were at a higher risk for premature death, a prospective cohort study has found.
While obesity remains a pressing public health threat, prevention and treatment are made difficult by the limits of the BMI to accurately measure excess adiposity, according to the study's authors.
'Waist circumference is a simple, inexpensive method to assess visceral adiposity and correlates well with visceral fat as assessed by imaging,' Aaron K. Aragaki, MS, and his colleagues wrote. Aragaki is a researcher at the Fred Hutchinson Cancer Center in Seattle.
The problem, wrote Aragaki and his colleagues, is that waist circumference is not often measured in the clinical setting. Further, 'Waist circumference would be especially valuable for staging of obesity risk if BMI-specific thresholds were available,' they wrote.
The investigators said that the current recommended waist circumference thresholds do not complement BMI because most adults diagnosed with obesity are already beyond these thresholds. Currently accepted waist circumference thresholds for overweight are 88 cm or above for women and 102 cm or above for men.
To stratify risk more accurately, new BMI-specific waist circumference threshold recommendations have been made recently by the International Atherosclerosis Society (IAS) and the International Chair on Cardiometabolic Risk (ICCR) Working Group on Visceral Obesity. They have proposed thresholds in women of 80 cm or greater, 90 cm or greater, 105 cm or greater, 115 cm or greater, and 115 cm or greater to correlate, respectively, with BMI categories: normal weight (18.5 to < 25), overweight (25 to < 30), obesity 1 (30 to < 35), obesity 2 (35 to < 40), and obesity 3 (≥ 40).
In men, they propose the corresponding waist measurements of 90 cm or greater, 100 cm or greater, 110 cm or greater, 125 cm or greater, and 125 cm or greater to correlate with the respective BMI categories.
A consensus statement issued in 2020 by the IAS and the ICCR suggested that prospective data were needed to further stratify BMI categories by waist circumference thresholds to improve mortality risk prediction compared with BMI categories.
To that end, Aragaki and his colleagues examined all-cause mortality data from the Women's Health Initiative (WHI), a large, national, multicenter, population-based study of generally healthy postmenopausal women (aged between 50 and 79 years), with enrollment from 1993 to 1998 and follow-up through 2021.
Data of 139,213 women from the WHI were distributed across three groups. There was a development cohort (N = 67,774) and two validation cohorts, one according to overweight and obesity prevalence, and another according to geography and diversity.
Validation Cohort 1 (N = 48,335) had half the prevalence of prior cardiovascular disease and cancer as the development group, but a higher rate of overweight or obesity (72.6% vs 59.1%). Validation Cohort 2 (N = 23,104) had nearly twice the number of women who identified as Black compared with the development group (12.7% vs 6.4%) and nearly three times the number of women who identified as Hispanic (9.1% vs 3.1%).
Aragaki and his colleagues analyzed annual all-cause mortality in the datasets and the National Death Index. They found that respective death rates at 10- and 20-year follow-up marks were 5808 and 22,124 in the development cohort; 3418 and 14,252 in Validation Cohort 1, and 2123 and 7668 in Validation Cohort 2.
Validation Cohort 1 had a higher prevalence of large waist circumference (21.9%) than Validation Cohort 2 (18.2%), according to currently accepted BMI-specific thresholds. Nearly all women with obesity 2 or obesity 3 had a waist circumference of 88 cm or larger, whereas women with a normal weight did not much exceed this waist circumference threshold.
Differences in the percentage of trunk fat between women with normal waist circumference and those with large waist circumference within the same BMI categories across centers were notable, ranging from 0.5 to 1.0 SDs.
Baseline risk for mortality at 10 and 20 years was highest in those with a prior history of disease and was lowest in those with no prior disease or preexisting condition across 5-year age groups, Aragaki and his colleagues found.
All estimated hazard ratios in the mortality model were associated with higher mortality risk compared with the baseline risk. When BMI categories > 30 were added to this model, they were positively associated with higher mortality risk in a dose-dependent manner compared with the BMI category of normal weight.
After stratification of BMI categories by waist circumference thresholds, hazard ratios were consistently greater for BMI categories with large waist circumference than their counterparts with normal ones. The mortality risk in women with normal weight or overweight and large waist circumferences was similar to that in women with obesity 1 and a normal waist circumference.
Mortality risk in those with obesity 1 and a large waist circumference was similar to that in women with obesity 3 and normal waist circumference.
Stratifying BMI categories by waist circumference thresholds improved mortality discrimination over BMI alone at 10 years for Validation Cohort 1, with the c-statistic increasing from 60.7% (95% CI, 59.5%-61.9%) to 61.3% (95% CI, 60.2%-62.5%), an improvement of 0.7% (95% CI, 0.3%-1.0%). The c-statistic is the agreement between the number of observed outcomes and predicted risk at 10 and 20 years, according to Aragaki and his colleagues.
Discrimination was not significantly improved for Validation Cohort 2, however, with a difference in c-statistics of 0.3% (95% CI, 0.2%-0.7%).
'Combining BMI and waist circumference assessments allows for more personalized decision making,' Aragaki and his colleagues wrote. 'Patients with a large waist circumference in any BMI category are at elevated cardiometabolic and mortality risk and may benefit from more aggressive interventions than those with similar BMIs but lower waist circumferences. Conversely, those with a normal waist circumference may require less aggressive care.'
The results of the study reinforce other data in favor of supplementing BMI with a second metric to more completely assess cardiometabolic health, a clinical obesity specialist told Medscape Medical News .
'BMI is a flawed criteria for diagnosis of obesity as it reflects total body mass but does not distinguish between fat and lean mass or where fat is distributed,' said Reema Hamid Dbouk, MD. 'Waist circumference is a surrogate for visceral fat, which is more metabolically active and linked to cardiometabolic risk and mortality.'
Dbouk is an assistant professor of obesity medicine at Emory School of Medicine and a Rollins Distinguished Clinician at the Emory Clinic, both in Atlanta.
'Waist circumference measurement is inexpensive, quick, and requires minimal training. The paper notes that embarrassment or discomfort among patients is low, particularly among older adults. Integration into EMRs and vital sign protocols could normalize its use. Patients may understand waist size more intuitively than BMI. Tracking waist circumference over time may be more encouraging, especially if muscle gain masks fat loss on the scale,' said Dbouk.
Dbouk said she thought the study was thorough, even if more data are still needed.
'Waist circumference-based thresholds may not fully account for differences in fat distribution by race/ethnicity or body habitus. For example, Asians may have higher metabolic risk at lower waist circumference. The thresholds are a step toward personalized risk assessment, but they may still require refinement to account for racial/ethnic differences in fat distribution and risk. More research is needed to validate waist circumference thresholds in broader populations, including men and younger individuals.'
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

24/7 Market News: LIXTE Biotech Advances Precision Oncology Pipeline with First Phase 1B/2 Trial Readout Expected in 2H 2025
24/7 Market News: LIXTE Biotech Advances Precision Oncology Pipeline with First Phase 1B/2 Trial Readout Expected in 2H 2025

Yahoo

time26 minutes ago

  • Yahoo

24/7 Market News: LIXTE Biotech Advances Precision Oncology Pipeline with First Phase 1B/2 Trial Readout Expected in 2H 2025

24/7 Market News Issues Corrected Information on Previously issued Press Release with same title DENVER, Aug. 14, 2025 (GLOBE NEWSWIRE) -- a pioneer in digital media dedicated to the swift distribution of financial market news and corporate information, spotlights LIXTE Biotechnology Holdings, Inc. (Nasdaq: LIXT), a clinical-stage pharmaceutical company focused on developing novel cancer therapies by targeting the modulation of key cellular pathways. 2H 2025 is shaping up to be a defining year for LIXTE. With a focus on its lead compound LB-100, a first-in-class small molecule inhibitor of protein phosphatase 2A (PP2A), a master regulator of cell signaling and DNA damage response. By inhibiting PP2A, LB-100 sensitizes tumors to DNA-damaging agents, including chemotherapy, radiation, and immunotherapy, LIXTE is targeting high-unmet needs in the $200 billion global oncology market (Grand View Research, 2025 projection). Potential upcoming catalysts in 2025, including a first trial result, position LIXTE as a potential disruptor in resistant cancers, where traditional treatments fail due to limited efficacy and toxicity. Upcoming Catalysts: Anticipated Trial Results in 2H 2025 1B/2 Trial – Ovarian Clear Cell Carcinoma (OCCC) Ovarian clear cell carcinoma is an aggressive and chemoresistant subtype of epithelial ovarian cancer, accounting for ~5–10% of all ovarian malignancies but disproportionately contributing to ovarian cancer mortality. The Phase 1B/2 study of LB-100 plus the checkpoint inhibitor dostarlimab (GSK) is designed leverage LB-100's synergistic enhancement of immune checkpoint blockade. Status: Enrolled, with interim safety completed Upcoming Milestone: Preliminary safety and efficacy data expected Q4 2025 Potential Market Impact: Global OCCC treatment market is projected to exceed $750 million by 2028 due to rising incidence and limited targeted therapies 1B/2 Trial – Advanced Soft Tissue Sarcoma (STS) Soft tissue sarcomas are a diverse and difficult-to-treat group of cancers arising from connective tissues. For patients with advanced or metastatic disease, prognosis remains Phase 1B/2 study evaluates LB-100 in combination with doxorubicin, the current standard of care, in patients with advanced STS. Status: Dose escalation completed. Upcoming Milestone: Safety report Q4 2025 Potential Market Impact: The global STS drug market is estimated to reach $2.1 billion by 2030, driven by the emergence of combination therapies and unmet medical need 1B Trial – Metastatic Microsatellite Stable (MSS) Colon Cancer MSS colon cancer, representing roughly 85% of metastatic colorectal cancer (mCRC), remains unresponsive to checkpoint inhibitors. LIXTE is conducting a Phase 1B trial assessing the safety and activity of LB-100 in combination with+ atezolizumab (Roche) (an ICI), seeking to overcome immune resistance in this cold tumor type. Status: Trial open, first patients recruited Potential Market Impact: The global colorectal cancer therapeutics market is expected to surpass $18 billion by 2030, with MSS disease representing the majority of treatment-resistant cases Platform Potential and Market Opportunity LIXTE's strategy of targeting PP2A to potentiate multiple treatment modalities positions LB-100 as a versatile combination agent with broad applicability across solid tumors. The platform's potential spans oncology subtypes with high unmet need, limited innovation, and growing incidence. Strong IP Position: Multiple issued and pending patents covering composition, methods of use, and combinations Pipeline Expansion: Additional tumor types and investigator-sponsored studies are under review, including glioblastoma. Partnership Potential: Ongoing discussions with academic institutions and biopharma partners for co-development opportunities Contact sales@ for Analyst Report coverage and other investor/public relations services. About LIXTE Biotechnology Holdings, Inc. LIXTE is a clinical-stage pharmaceutical company focused on discovering and developing innovative cancer therapies targeting the protein phosphatase 2A (PP2A) pathway, a previously underexplored avenue in cancer treatment. The company's lead compound, LB-100, is a first-in-class PP2A inhibitor that has demonstrated strong preclinical results and early-stage clinical tolerability. LIXTE is currently advancing proof-of-concept trials in Ovarian Clear Cell Carcinoma, Metastatic Colon Cancer, and Advanced Soft Tissue Sarcoma. More information can be found at: 24/7 MARKET NEWS, INC DisclaimerPlease go to for further LIXT information and LIXT disclosure information. Cautionary Note Regarding Forward-Looking Statements This press release contains forward-looking statements that are subject to various risks and uncertainties. Such statements include statements regarding the Company's ability to grow its business and other statements that are not historical facts, including statements which may be accompanied by the words "intends," "may," "will," "plans," "expects," "anticipates," "projects," "predicts," "estimates," "aims," "believes," "hopes," "potential" or similar words. Actual results could differ materially from those described in these forward-looking statements due to a number of factors, including without limitation, the Company's ability to continue as a going concern, general economic conditions, and other risk factors detailed in the Company's filings with the SEC. The forward-looking statements contained in this press release are made as of the date of this press release, and the Company does not undertake any responsibility to update such forward-looking statements except in accordance with applicable law. CONTACT: CONTACT: 24/7 Market News Editor@ in to access your portfolio

Draft of White House Report Suggests Kennedy Won't Push Strict Pesticide Regulations
Draft of White House Report Suggests Kennedy Won't Push Strict Pesticide Regulations

New York Times

time28 minutes ago

  • New York Times

Draft of White House Report Suggests Kennedy Won't Push Strict Pesticide Regulations

A highly anticipated White House report on the health of American children would stop short of proposing direct restrictions on ultraprocessed foods and pesticides, which the health secretary, Robert F. Kennedy Jr., has called major threats, according to a draft of the document that was reviewed by The New York Times. The report, if adopted, would be good news for the food and agriculture industries, which feared far more restrictive proposals than the ones outlined in the draft. Through his 'Make America Healthy Again' movement, Mr. Kennedy has sought to overhaul the nation's diet by pushing those industries to make major changes. The draft includes an array of policy proposals calling for research into topics like electromagnetic radiation, children's oral health, the role of the microbiome and the health effects of air quality and microplastics. It also recommends government action on a wide range of issues, including initiatives to increase breastfeeding rates, address infertility, promote physical activity and educate the public on the effects of vaping. Questions about a possible push for new pesticide regulations were raised in May when the White House released an initial report, from a presidential commission chaired by Mr. Kennedy, that raised strong concerns about possible links between pesticides and childhood diseases. It also linked the dominance of ultraprocessed foods in children's diets to a range of chronic diseases. Those findings touched off tensions between Mr. Kennedy's movement and Republican lawmakers who have traditionally drawn support from powerful agriculture, food and drug lobbyists. The Times obtained the draft of the new report from a former federal official. An industry official confirmed that it was nearly identical to a copy the administration had recently shown the official at the White House. Kush Desai, a White House spokesman, on Thursday would not verify the draft. At this stage, any draft would go through a number of revisions before it is finalized. The document The Times reviewed was labeled 'pre-decisional' and dated Aug. 6. Called the 'Make Our Children Healthy Again Strategy,' the report comes from the commission led by Mr. Kennedy, which includes cabinet secretaries and agency heads from across the government. The White House has not said when the report will be made public, though it was to have been presented to President Trump on Tuesday, the deadline set by Mr. Trump's executive order establishing the 'MAHA Commission.' The final report is expected to be released in the coming weeks. The draft report says that environmental regulators will work with 'food and agricultural stakeholders' to ensure that the public is aware of and confident in existing pesticide review procedures. It described those procedures as 'robust' and did not propose new restrictions. It also says the Trump administration will back research on technologies to try to help farmers reduce pesticide use and on the health effects of Americans' cumulative exposure to chemicals. After the first report was published in May, agriculture groups, including the American Soybean Association and the National Corn Growers Association, urged the Trump administration to listen to farmers as the commission prepared its follow-up report outlining a strategy. The draft reviewed by The Times does not mention how the proposed research and the new policy initiatives would be funded or how much money might be allocated to them. But it says that the Department of Health and Human Services will form a working group to evaluate 'overprescription trends' involving mental health medications, such as S.S.R.I.s and stimulants, for children. It reiterates Mr. Kennedy's pledge to study the 'root causes' of autism. Mr. Kennedy has spent much of his tenure as health secretary characterizing modern American childhood as a state of stress and sickness, with children mainly eating ultraprocessed food, which he has called 'poison,' tethered to screens and reliant on pills and shots. And he has railed against the pharmaceutical industry, which he says exerts undue influence over scientific research, all while the Trump administration has decimated funding for many academic research programs. Mr. Kennedy has also condemned scientific experts. In June, he fired all the members of an influential vaccine advisory panel. The first report, from May, reflected many of Mr. Kennedy's key talking points. It was heavily scrutinized. While some scientists applauded its focus on flaws within the American food system, many noted it misrepresented the scientific consensus on issues like vaccines. The report also cited studies that did not exist. In recent weeks, Mr. Kennedy's aides and allies have publicized what they described as the administration's most significant steps to improve American health. These include persuading some food makers to phase out petroleum-based food dyes, working with several states to remove soda and candy from their food stamp programs and trying to tighten oversight of food additives. The draft reiterates that the administration will continue these efforts. Some researchers have cautioned that such steps may not do much to improve the overall healthfulness of the American food supply. Ultraprocessed foods, which make up about 62 percent of the calories consumed by U.S. children, are explicitly mentioned in the draft of the second report only once, in a line about the administration's effort to define them. The near-omission of ultraprocessed foods from the draft report raises questions about the administration's appetite for regulation, which the food industry is likely to vehemently oppose. The draft does describe prioritizing 'whole, healthy' foods in federal programs like those providing meals in schools. It suggests offering these foods in 'MAHA boxes' for food stamp recipients. The draft touches on a number of other topics, including vaccines, a focus of Mr. Kennedy's. It says the health department will develop a framework for 'Ensuring America has the Best Childhood Vaccine Schedule.' Mr. Kennedy, one of the nation's most prominent vaccine skeptics, recently pledged to overhaul the nation's system to compensate people harmed by vaccines. Earlier this month, he canceled nearly $500 million in contracts for mRNA vaccines. The draft report also suggests that the government will consider developing guidelines that would limit marketing of unhealthy foods directly to children and will more vigorously enforce restrictions around direct-to-consumer drug advertising. It says the Centers for Disease Control and Prevention will update its recommendations on fluoride in water. On Tuesday, Calley Means, a senior adviser to Mr. Kennedy, spoke at a Heritage Foundation event on the role of agriculture in public health, presenting farmers as key players in American health care. 'We are not going to win if the soybean farmers and the corn growers are our enemy,' he said. There are signs that the report, as drafted, could land with a thud among Mr. Kennedy's followers. In July, 500 people, including leaders of advocacy groups aligned with Mr. Kennedy's movement, sent a letter to Mr. Kennedy and other members of the White House commission urging them to ban pesticides like glyphosate. Hundreds of people tied to the MAHA movement, including Vani Hari, a prominent food activist and MAHA influencer, also sent a letter addressed to Mr. Trump on Monday urging him to take action against protections for pesticide manufacturers. Over the first six months of his presidency, Mr. Trump has largely supported Mr. Kennedy's decisions, after urging him during the campaign to 'go wild' on health. This month, though, after Mr. Kennedy canceled the contracts for mRNA vaccines, Mr. Trump told reporters that the mRNA coronavirus vaccine development initiative from his first term, Project Warp Speed, was 'one of the most incredible things ever done in this country.' He said he had scheduled a meeting with Mr. Kennedy to discuss the cancellations. While Mr. Trump convened the commission, and put Mr. Kennedy at the helm, he does not have to follow its guidance. 'Unlike other administrations, we will not be silenced or intimidated by the corporate lobbyists or special interests,' Mr. Trump said in May during an event celebrating the release of the commission's first report. 'I want this group to do what they have to do.' 'In some cases, it won't be nice, or it won't be pretty,' he added, 'but we have to do it.'

Bindi Irwin reveals major health update: 'Felt utterly ashamed'
Bindi Irwin reveals major health update: 'Felt utterly ashamed'

Yahoo

time30 minutes ago

  • Yahoo

Bindi Irwin reveals major health update: 'Felt utterly ashamed'

Bindi Irwin has shared a major health update in her long battle with endometriosis. Taking to Instagram, the Wildlife Warrior shared a selfie, revealing she was "finally" feeling better after undergoing two major surgeries. "13 years of fighting for answers. 51 endometriosis lesions, a chocolate cyst, and my appendix were all removed across two surgeries with [Dr. Seckin]," she began her lengthy caption. "My hernia from giving birth that was unzipping - was taken care of. I can FINALLY say that I'm feeling better. Genuinely healing. I can function in everyday life without wanting to throw up or pass out from the pain. Slowly, slowly gaining my strength back." She continued, "I cannot express the gravity of my emotions as I am beginning to recognise myself again. I felt utterly ashamed as a teenager and young adult being told that my pain was just part of being a woman. I felt lesser. I felt hurt. I felt weak. That is not ok. "Young girls and women shouldn't feel alone with pain in the driver's seat of their lives. We need to take away the stigma of talking about women's health. It's time to have open discussions and make change on a global scale." RELATED: Bindi Irwin has fans in tears with emotional admission about Robert Irwin: 'Sobbing' Robert Irwin shares sweet tribute to sister Bindi Irwin after major surgery: 'Crippling' Bindi Irwin reveals she was 'really sick' for '10-plus years': 'Doctors didn't know' Bindi was previously forced to pull out of the Steve Irwin Gala in Las Vegas in May for surgery, leaving her brother Robert Irwin to host solo. At the time, Robert shared a tribute to his sister that read: "Happy to see you on the up and up, Bindi. You face every hurdle head on, take it in your stride and inspire us." Bindi commented on the post, "One day at a time. Tremendously grateful for your support. You're the best." Bindi Irwin's fans praise her bravery Fans commented on Bindi's post, sharing their admiration, with one person writing, "So proud of you for speaking up and sharing your journey." "I could not think of a better ambassador and role model for women going through this disease than you," another said. "So proud of you and excited for your new beginning, you have bloomed." "Thank you for sharing your story," a third wrote. "We need to keep advocating for every single person out there struggling & being dismissed!" "Thank you for all that you do to advocate for the endometriosis community!" someone else wrote. "You have brought so much awareness to this disease." "I am so sorry you struggled and were in pain," another said. "I am so happy you are healing. You are a very special soul - thank you so much for sharing your story and giving a voice to what affects so many women." Australia Zoo also commented, "Thank you Bindi for your strength and kindness in sharing your personal journey and thus allowing a light to shine on women's health! We LOVE that you are healing, and your bravery is encouraging others to speak out and seek answers." View this post on Instagram A post shared by Not Gonna Lie with Kylie Kelce (@nglwithkylie) What is endometriosis "Endometriosis is a disease in which tissue similar to the lining of the uterus grows outside the uterus," according to the World Health Organisation. "It can cause severe pain in the pelvis and make it harder to get pregnant. "Endometriosis can start at a person's first menstrual period and last until menopause. With endometriosis, tissue similar to the lining of the uterus grows outside the uterus. This leads to inflammation and scar tissue forming in the pelvic region and (rarely) elsewhere in the body." The cause of endometriosis is unknown, and unfortunately, there is no way to prevent it. There is also no cure, and it can only be treated with medication or surgery. Some people will not experience symptoms, but for those who do, it's often pain in the lower part of the belly. SHOP: 🏉 Rugby fan's huge airport surprise after landing in Sydney: 'Surreal' 🛏️ Expert reveals secret to the best night's sleep: 'Wouldn't choose anything else' 🦥 Boody's new range in sizes S to XL are 'the softest sets you'll ever wear': 'Comfy and chic' WHO adds, "It can decrease quality of life due to severe pain, fatigue, depression, anxiety and infertility. Some individuals with endometriosis experience debilitating pain that prevents them from going to work or school." Pain can also be noticeable during a period, during or after sex, or when going to the toilet. Some people also experience: chronic pelvic pain heavy bleeding during periods or between periods trouble getting pregnant bloating or nausea fatigue depression or anxiety Symptoms can improve after menopause, but not always.

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store